Canada Awards SIGA Up to $15 Million for TPOXX Supply Through 2031

On October 28, 2026, Public Services and Procurement Canada (PSPC) awarded SIGA Technologies, Inc. a new contract to supply oral TPOXX® (tecovirimat) on behalf of the Canadian Department of National Defence (CDND). The procurement is being conducted through CDND’s Strategic Medical Countermeasures Program and runs through March 31, 2031. TPOXX is an antiviral medication used to treat smallpox, and the purchase supports Canada’s continued access to an approved medical countermeasure for its military. For government contractors and suppliers, the award is a concrete signal that Canada is maintaining a long-term procurement pathway for smallpox preparedness rather than relying solely on prior inventory purchases.

The contract provides for purchases of up to approximately $15 million. About $9 million is identified as firm commitments over the first three years, while approximately $6 million is subject to options that CDND may exercise. That distinction matters when evaluating demand certainty: the total ceiling indicates potential contract scale, but the firm portion is the more reliable measure of committed business. Suppliers assessing the opportunity should avoid treating the full $15 million as guaranteed revenue and should account for option exercise when modeling expected demand, production planning, and supporting supply-chain capacity.

This is PSPC’s second TPOXX contract on behalf of CDND. In April 2020, PSPC awarded SIGA a contract for purchases of up to approximately $14 million of oral TPOXX, with final delivery under that earlier agreement completed in 2025. The new follow-on award therefore continues an established Canadian supplier relationship and provides a defined procurement horizon extending to 2031. SIGA’s incumbent position is relevant to competitors and adjacent suppliers: the award demonstrates continuity in Canada’s current sourcing approach, while the contract’s duration may create planning opportunities for firms that can support pharmaceutical production, distribution, storage, or other relevant supply-chain requirements.

The procurement also aligns with Canada’s broader health-security and defence-preparedness objectives. The source announcement states that Canada’s Defence Industrial Strategy recognizes the importance of maintaining access to critical medical countermeasures. SIGA Chief Executive Officer Diem Nguyen said: “Canadian Armed Forces members are often among the first called upon in a public health emergency, and ready access to an approved smallpox antiviral helps ensure they can safely and effectively carry out that mission.” The statement frames the purchase as both a medical readiness measure and a defence-support requirement. The award does not establish the timing or quantity of individual deliveries beyond the disclosed contract terms, so interested firms should monitor future procurement notices and option activity for additional indications of realized demand.

• PSPC awarded SIGA Technologies, Inc. a follow-on contract for oral TPOXX (tecovirimat) on behalf of CDND.
• The contract runs through March 31, 2031, providing a defined period for procurement and supply-chain planning.
• The value is up to approximately $15 million: about $9 million in firm commitments over the first three years and approximately $6 million subject to options.
• The optional portion is not guaranteed; contractors should distinguish ceiling value from committed demand when forecasting revenue or capacity needs.
• The purchase is conducted through CDND’s Strategic Medical Countermeasures Program and supports Canadian smallpox preparedness.
• This is PSPC’s second TPOXX contract for CDND; the prior agreement, awarded in April 2020 for up to approximately $14 million, reached final delivery in 2025.
• Canada’s Defence Industrial Strategy identifies access to critical medical countermeasures as part of broader health-security and defence-preparedness objectives, according to the announcement.
• SIGA’s established supplier relationship is a factor for competitors assessing related opportunities; supporting pharmaceutical supply-chain capabilities may be relevant over the contract period.
• SIGA CEO Diem Nguyen emphasized the Canadian Armed Forces’ role in public health emergencies and the operational value of ready access to an approved smallpox antiviral.